Robeco Institutional Asset Management B.V. grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,647 shares of the medical equipment provider’s stock after purchasing an additional 3,336 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Hologic were worth $797,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. Koch Industries Inc. grew its holdings in shares of Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares during the last quarter. Chevy Chase Trust Holdings Inc. grew its holdings in shares of Hologic by 1.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock valued at $8,975,000 after purchasing an additional 3,391 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Hologic by 15.5% during the third quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock worth $10,458,000 after buying an additional 38,283 shares during the period. Cipher Capital LP boosted its position in shares of Hologic by 57.9% during the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after buying an additional 43,146 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Hologic by 66.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock worth $458,000 after buying an additional 4,984 shares during the period. 93.84% of the stock is currently owned by institutional investors and hedge funds.
HOLX has been the subject of a number of research analyst reports. Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research report on Thursday, January 4th. Goldman Sachs Group raised shares of Hologic from a “buy” rating to a “conviction-buy” rating and boosted their target price for the company from $45.00 to $50.00 in a research note on Friday, December 8th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a research note on Wednesday, December 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $48.00 price target (up from $46.00) on shares of Hologic in a research note on Tuesday, December 5th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $44.00 price objective on shares of Hologic in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $48.00.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded up $0.23 during trading on Thursday, hitting $38.03. 3,320,700 shares of the company were exchanged, compared to its average volume of 2,948,659. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,700.00, a price-to-earnings ratio of 14.76, a P/E/G ratio of 1.71 and a beta of 0.77. Hologic, Inc. has a fifty-two week low of $35.33 and a fifty-two week high of $46.80.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. During the same quarter last year, the business posted $0.52 earnings per share. Hologic’s revenue for the quarter was up 7.7% compared to the same quarter last year. equities analysts anticipate that Hologic, Inc. will post 2.25 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://weekherald.com/2018/02/15/hologic-inc-holx-shares-bought-by-robeco-institutional-asset-management-b-v.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.